An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria

• Published in: Mini reviews in medicinal chemistry Vol. 20; no. 18; p. 1908
• Main Authors: AlMatar, Manaf, Albarri, Osman, Makky, Essam A, Var, Işıl, Köksal, Fatih
• Format: Journal Article
• Language: English
• Published: Netherlands 2020
• Subjects: Anti-Bacterial Agents - chemical synthesis; Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Cefiderocol; Cephalosporins - chemical synthesis; Cephalosporins - chemistry; Cephalosporins - pharmacology; Drug Resistance, Multiple, Bacterial - drug effects; Gram-Negative Bacteria - drug effects; Microbial Sensitivity Tests; Molecular Structure; β-lactam antibiotics; adverse effects; clinical studies; Cefiderocol; MDR; antimicrobial activity; gram negative
• ISSN: 1875-5607
• DOI: 10.2174/1389557520666200818211405

The need for new therapeutics and drug delivery systems has become necessary owing to the public health concern associated with the emergence of multidrug-resistant microorganisms. Among the newly discovered therapeutic agents is cefiderocol, which was discovered by Shionogi Company, Japan as an injectable siderophore cephalosporin. Just like the other β-lactam antibiotics, cefiderocol exhibits antibacterial activity via cell wall synthesis inhibition, especially in Gram negative bacteria (GNB); it binds to the penicillin-binding proteins, but its unique attribute is that it crosses the periplasmic space of bacteria owing to its siderophore-like attribute; it also resists the activity of β-lactamases. Among all the synthesized compounds with the modified C-7 side chain, cefiderocol (3) presented the best and well-balanced activity against multi-drug resistant (MDR) Gram negative bacteria, including those that are resistant to carbapenem. İn this article, an overview of the recent studies on cefiderocol was presented.